Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YD0743 for sepsis-associated ARDS (Phase II, randomized, placebo-controlled)
CTR20254877Phase 2Active
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of YD0743 in acute respiratory distress syndrome (ARDS) and sepsis (3 arms), sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Primary endpoint: Ventilator-free time within 28 days. Started Feb 2026; status: active.
02
Drugs
YD0743
03
Conditions
acute respiratory distress syndrome (ARDS)sepsis
Beyond the preview
Go deeper on CTR20254877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254877.